Clinical presentation, videourodynamic characteristics, and treatment outcome in men with interstitial cystitis-like lower urinary tract symptoms

Yu, Wan-Ru; Chang, Wei‐Chuan; Kuo, Hann‐Chorng

doi:10.1007/s11255-022-03294-2

Cited by 3 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous functional study of male IC/BPS patients, most of the patients were found to have LUTD such as DO, BND, dysfunctional voiding, and PRES according to the precision diagnosis of a videourodynamic study. The results also reflect that bladder outlet dysfunction might coexist with (or secondary to) the bladder inflammation of IC/BPS but might not be the etiology of IC/BPS [5].…”

Section: Discussionmentioning

confidence: 80%

“…Male patients with IC-like LUTS are more commonly misdiagnosed as having anatomical BOO and surgical intervention might be mistakenly performed if the initial medical treatment targeting BOO fails. Compared with the LUTS in female IC/BPS patients, the incidences of DO, voiding dysfunctions, and urgency LUTS are significantly higher in male IC/BPS patients [5]. The higher incidence of DO and storage LUTS in male IC/BPS patients might result in an enhanced guarding effect of the bladder neck, urethral striated muscle, or pelvic floor muscles, which ultimately causes a dysfunctional bladder outlet and voiding symptoms.…”

Section: Discussionmentioning

confidence: 91%

“…Bladder inflammation has been considered as the main pathogenesis of IC/BPS, resulting in bladder urothelial denudation and symptoms of bladder pain and frequency [14]. Nevertheless, the definitive etiology of IC/BPS remains unclear and a poor treatment outcome remains a challenge to urologists [5]. Chronic bladder inflammation can lead to central sensitization, resulting in sensory nerve activation and bladder hypersensitivity, which may induce afferent nerve overactivity [14,26] and, in a part of patients, cause efferent nerve activation of the bladder neck and urethral sphincter, resulting in a high rate of voiding dysfunction in patients with IC/BPS [27].…”

Section: Discussionmentioning

confidence: 99%

“…Over half of men with LUTS might also result from hypersensitive bladder (HSB), overactive bladder (OAB), underactive bladder, or urethral sphincter dysfunction [4]. Among male patients with storage LUTS involving bladder pain who do not respond to conventional medications for BOO or bladder dysfunction, interstitial cystitis/bladder pain syndrome (IC/BPS) should be considered [5].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions

Jiang

Jhang

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

To analyze the urinary biomarkers in men with lower urinary-tract symptoms (LUTS) and identify interstitial cystitis/bladder pain syndrome (IC/BPS) from the other lower urinary-tract dysfunctions (LUTDs) by the levels of characteristic urinary biomarkers. In total, 198 men with LUTS were prospectively enrolled and urine samples were collected before intervention or medical treatment. Videourodynamic studies were routinely performed and the LUTDs were diagnosed as having bladder-outlet obstruction (BOO) such as bladder-neck dysfunction, benign prostatic obstruction, or poor relaxation of external sphincter (PRES); and bladder dysfunction such as detrusor overactivity (DO), hypersensitive bladder (HSB), and IC/BPS. Patients suspicious of IC/BPS were further confirmed by cystoscopic hydrodistention under anesthesia. The urine samples were investigated for 11 urinary inflammatory biomarkers including eotaxin, IL-6, IL-8, CXCL10, MCP-1, MIP-1β, RANTES, TNF-α, NGF, BDNF, and PGE2; and 3 oxidative stress biomarkers 8-OHdG, 8-isoprostane, and TAC. The urinary biomarker levels were analyzed between LUTD subgroups and IC/BPS patients. The results of this study revealed that among the patients, IC/BPS was diagnosed in 48, BOO in 66, DO in 25, HSB in 27, PRES in 15, and normal in 17. Patients with BOO had a higher detrusor pressure and BOO index than IC/BPS, whereas patients with IC/BPS, BOO, and DO had a smaller cystometric bladder capacity than the PRES and normal subgroups. Among the urinary biomarkers, patients with IC/BPS had significantly higher levels of eotaxin, MCP-1, TNF-α, 8-OHdG, and TAC than all other LUTD subgroups. By a combination of different characteristic urinary biomarkers, TNF-α, and eotaxin, either alone or in combination, had the highest sensitivity, specificity, positive predictive value, and negative predictive value to discriminate IC/BPS from patients of all other LUTD subgroups, BOO, DO, or HSB subgroups. Inflammatory biomarker MCP-1 and oxidative stress biomarkers 8-OHdG and TAC, although significantly higher in IC/BPS than normal and PRES subgroups, did not have a diagnostic value between male patients with IC/BPS and the BOO, DO, or HSB subgroups. The study concluded that using urinary TNF-α and eotaxin levels, either alone or in combination, can be used as biomarkers to discriminate patients with IC/BPS from the other LUTD subgroups in men with LUTS.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions

Jiang

Jhang

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Male LUTS include symptoms of bladder storage and emptying, which could be a result of bladder and bladder outlet dysfunctions. Although men with voiding predominant LUTS are usually diagnosed as having clinical benign prostatic hyperplasia (BPH), half of the patients with LUTS are actually resulted from different LUTD such as DO, DU, HSB, BND, DV, poor urethral sphincter relaxation, or IC/BPS[ 3 , 83 , 84 , 85 ]. Behind these LUTD, the pathophysiology of chronic bladder ischemia, BOO-induced bladder fibrosis, increased sensory hyperactivity, and neurogenic inflammation might produce different urinary proteins and biomarkers that lead to different functional and morphological modulations[ 24 , 86 , 87 , 88 , 89 , 90 ].…”

Section: Ale Lower Urinary Tract Dysfunctionsmentioning

confidence: 99%

Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction

Yu,

Jiang,

Jhang

et al. 2023

Tzu Chi Medical Journal

Self Cite

View full text Add to dashboard Cite

A precision diagnosis of lower urinary tract dysfunctions (LUTD) such as bladder outlet obstruction, detrusor overactivity (DO), interstitial cystitis/bladder pain syndrome (IC/BPS), dysfunctional voiding (DV), or detrusor underactivity (DU) needs invasive videourodynamic study. Exploring non-invasive tools to help screening LUTD is necessary for clinicians in their daily practice. This article reviews recently clinical studies of using urinary inflammatory proteins and oxidative stress biomarkers in the identification of specific LUTD among men and women with lower urinary tract symptoms (LUTS). Some important findings have been reported: (1) Using urine chemokines CXCL-1 and interleukin-8 (IL-8), we may discriminate overactive bladder (OAB) symptoms in women between DO and urinary tract infection. (2) Urinary levels of oxidative stress biomarkers such as 8-hydroxydeoxyguanosine (8-OHdG) and 8-isoprostane have a potential being used as a tool to identify women with mixed DO and stress urinary incontinence. (3) Urine levels of total antioxidant capacity (TAC), and prostaglandin E2 (PGE2) are positively correlated with voiding detrusor pressure in patients with DU. (4) Urine levels of brain-derived neurotrophic factor (BDNF) and PGE2 were significantly higher in the DU patients with detrusor function recovery. (5) Women with DV had higher urinary levels of tumor necrosis factor-alpha (TNF-α) and 8-OHdG, and urinary IL-2 level was significantly lower. (6) Urine level of 8-isoprostane was higher in the patients with idiopathic DO and neurogenic DO. (7) Higher urine cytokine levels of monocyte chemoattractant protein-1 (MCP-1), regulated on activation, normal T-cell expressed and secreted (RANTES), CXCL-10, IL-7, and eotaxin-1 in patients with IC/BPS than controls. (8) The urine levels of IL-8, CXCL-10, BDNF, IL-6, and RANTES were significantly higher in patients with Hunner’s IC than non-Hunner’s IC. (9) Male patients with IC/BPS had a significantly higher level of eotaxin, MCP-1, TNF-α, 8-OHdG, and TAC. Combining a higher eotaxin and a higher TNF-α can provide a satisfactory diagnostic value in discriminating IC/BPS from other LUTD in men. These studies provide evidence that measurement of cluster of urine biomarkers could be used as a diagnostic tool to differentiate different LUTD in patients with similar LUTS.

show abstract

Hyaluronan nanoplatelets exert an intrinsic anti-inflammatory activity in a rat model of bladder painful syndrome/interstitial cystitis

Diaz-Salmeron

Cailleau

Denis

et al. 2023

Journal of Controlled Release

View full text Add to dashboard Cite

Clinical presentation, videourodynamic characteristics, and treatment outcome in men with interstitial cystitis-like lower urinary tract symptoms

Cited by 3 publications

References 28 publications

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions

Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction

Hyaluronan nanoplatelets exert an intrinsic anti-inflammatory activity in a rat model of bladder painful syndrome/interstitial cystitis

Contact Info

Product

Resources

About